Global Blood Therapeutics

Traded on the St. Petersburg Stock Exchange
lobal Blood Therapeutics (GBT) is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments.
Global Blood Therapeutics stock price chart
+165%
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential

Global Blood Therapeutics balance sheet

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Capitalization, $
Capitalization, $
Enterprise Value
Book Value
Shareholders Book Value
Current liabilities
Noncurrent liabilities
Total liabilities
Debt
Cash and cash equivalents
Net debt
Assets
Total ordinary shares
Ordinary share price

Global Blood Therapeutics cash flows

Report period2016 2017 2018 2019 2020 2021
End date of the reporting period
Sales
Gross profit
Operation Income
Earnings
Shareholders earnings
EBITDA
Operation Cashflow
Capital expenditure
Free Cash Flow
EPS

Global Blood Therapeutics multipliers

Report period2016 2017 2018 2019 2020 2021
P/E
E/P
P/B
P/S
P/FCF
L/A
Debt-To-Equity
Net Debt/EBITDA
EV/EBITDA

Global Blood Therapeutics profitability

Report period2016 2017 2018 2019 2020 2021
ROA
ROE
ROS
Gross margin
EBITDA Margin
Operating margin
Global Blood Therapeutics assets
Global Blood Therapeutics cash flows

Global Blood Therapeutics shares

TickerNameTypeNominal valueISINPrice
GBT:USGlobal Blood Therapeutics, Inc.Common share-US37890U1088$68.49
Global Blood Therapeutics news
08.08.2022
Pfizer acquires Global Blood Therapeutics for $5.4, or $68.5 per share. The transaction is subject to customary closing conditions.
Source: {source} pictogram ir.gbt.com
05.05.2022
The loss of Global Blood Therapeutics under GAAP for the 3 months of 2022 was $81.423 million, up 8.7% from $74.93 million in the previous year. Revenue increased 41.3% to $55.16 million from $39.043 million a year earlier.
Source: {source} pictogram ir.gbt.com
24.02.2022
Global Blood Therapeutics reported a GAAP loss of $303.091 million for 2021, up 22.4% from $247.553 million in the previous year. Revenue increased 57.3% to $194.749 million from $123.803 million a year earlier.
Source: {source} pictogram ir.gbt.com
16.02.2022
Global Blood Therapeutics has received European Commission approval for Oxbryta. The drug is intended to treat hemolytic anemia due to sickle cell disease in people 12 years and older. The approval is valid in all EU countries as well as Iceland, Liechtenstein and Norway.
Source: {source} pictogram ir.gbt.com
General information
Company nameGlobal Blood Therapeutics
Tags#pharmacy
SectorHealth Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals
Business address171 OYSTER POINT BLVD, SUITE 300 SOUTH SAN FRANCISCO CA 94080 650741-7700
Mailing address171 OYSTER POINT BLVD, SUITE 300 SOUTH SAN FRANCISCO CA 94080
Websitewww.globalbloodtx.com
Information disclosurewww.sec.gov